Orion Pushing Ahead In Prostate Cancer, R&D Reorganized

Extending Nubeqa's Indications

Finland’s Orion Corporation is highlighting its prostate cancer and other oncology candidates in its reorganized R&D.

Espoo, Finland
Espoo, Finland, Where Orion Corp Is Headquartered • Source: Shutterstock

Finland’s mid-sized pharmaceutical company, Orion Corporation, which develops and markets across branded products, generics and APIs, is evaluating two more potential prostate cancer therapies, ODM-208, and ODM-209, and is joining collaborator Bayer AG on the evaluation of the marketed product, Nubeqa (darolutamide), in a broader range of prostate cancer patients. 

ODM-208 and ODM-209 are selective hormone synthesis inhibitors, or CYP11A1 inhibitors, and are first-in-class candidates, the company noted during its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

Boehringer Scores First Approval For Targeted Oral Drug In HER2-Mutant NSCLC

 

The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.

More from Therapy Areas

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.